Ratings OptimizeRx Corporation

Equities

OPRX

US68401U2042

Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
8.8 USD -3.93% Intraday chart for OptimizeRx Corporation -5.88% -38.50%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Internet Services

1st Jan change Capi. Investor Rating ESG Refinitiv
-38.50% 160M
C+
+19.48% 404B
B
+12.57% 144B
A-
+19.74% 104B
C-
+14.17% 81.99B
B+
+53.81% 57.53B
B-
+29.55% 51.76B
C+
+3.38% 36.89B
B
+14.29% 31.71B
C+
-11.88% 22.28B
C
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. OPRX Stock
  4. Ratings OptimizeRx Corporation